366 related articles for article (PubMed ID: 22251703)
1. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells lead the charge against tumors.
Jiménez-Baranda S; Silva IP; Bhardwaj N
J Clin Invest; 2012 Feb; 122(2):481-4. PubMed ID: 22251700
[TBL] [Abstract][Full Text] [Related]
3. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
Kalb ML; Glaser A; Stary G; Koszik F; Stingl G
J Immunol; 2012 Feb; 188(4):1583-91. PubMed ID: 22231699
[TBL] [Abstract][Full Text] [Related]
4. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
5. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
6. The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway.
Ruscanu S; Pascale F; Bourge M; Hemati B; Elhmouzi-Younes J; Urien C; Bonneau M; Takamatsu H; Hope J; Mertens P; Meyer G; Stewart M; Roy P; Meurs EF; Dabo S; Zientara S; Breard E; Sailleau C; Chauveau E; Vitour D; Charley B; Schwartz-Cornil I
J Virol; 2012 May; 86(10):5817-28. PubMed ID: 22438548
[TBL] [Abstract][Full Text] [Related]
7. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
8. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
Fishelevich R; Zhao Y; Tuchinda P; Liu H; Nakazono A; Tammaro A; Meng TC; Lee J; Gaspari AA
J Immunol; 2011 Aug; 187(4):1664-73. PubMed ID: 21765012
[TBL] [Abstract][Full Text] [Related]
11. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
[TBL] [Abstract][Full Text] [Related]
12. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.
Stary G; Bangert C; Tauber M; Strohal R; Kopp T; Stingl G
J Exp Med; 2007 Jun; 204(6):1441-51. PubMed ID: 17535975
[TBL] [Abstract][Full Text] [Related]
13. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Aspord C; Tramcourt L; Leloup C; Molens JP; Leccia MT; Charles J; Plumas J
J Invest Dermatol; 2014 Oct; 134(10):2551-2561. PubMed ID: 24751730
[TBL] [Abstract][Full Text] [Related]
15. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
Ma F; Zhang J; Zhang J; Zhang C
Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis.
Nehmar R; Alsaleh G; Voisin B; Flacher V; Mariotte A; Saferding V; Puchner A; Niederreiter B; Vandamme T; Schabbauer G; Kastner P; Chan S; Kirstetter P; Holcmann M; Mueller C; Sibilia J; Bahram S; Blüml S; Georgel P
Arthritis Rheumatol; 2017 Nov; 69(11):2124-2135. PubMed ID: 28777892
[TBL] [Abstract][Full Text] [Related]
17. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
18. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.
Rabeony H; Pohin M; Vasseur P; Petit-Paris I; Jégou JF; Favot L; Frouin E; Boutet MA; Blanchard F; Togbe D; Ryffel B; Bernard FX; Lecron JC; Morel F
Eur J Immunol; 2015 Oct; 45(10):2847-57. PubMed ID: 26147228
[TBL] [Abstract][Full Text] [Related]
19. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.
Heib V; Becker M; Warger T; Rechtsteiner G; Tertilt C; Klein M; Bopp T; Taube C; Schild H; Schmitt E; Stassen M
Blood; 2007 Aug; 110(3):946-53. PubMed ID: 17446350
[TBL] [Abstract][Full Text] [Related]
20. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]